Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q1 2021 · 10-Q
Revenue$512.14K$512.14K−38.7% vs Q1 2020 Net Income$370.65K$370.65KN/M vs Q1 2020 EPS Diluted$0.02$0.02N/M vs Q1 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
Operating Cash Flow-$795,228N/M Free Cash Flowderived-$881,997N/M Margins · derivedGross margin35.6%+103.1 pt vs Q1 2020
Operating margin-213.2%+101.9 pt vs Q1 2020
Net margin72.4%+409.9 pt vs Q1 2020
ended Mar 31, 2021 · filed May 24, 2021 · 54 d after period end